Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30488129 | 1.00 | CYP4F2 (0.43) | CYP4F2CYP4A11IDO1ABL1PNMT | |
| SCHEMBL20570318 | 0.82 | PNMT (0.42) | IDO1ABL1PNMTTAAR1ALDH1A1 | |
| SCHEMBL3745838 | 0.81 | IDO1 (0.38) | IDO1ABL1PNMTTAAR1TSHR | |
| SCHEMBL507688 | 0.81 | CYP4F2 (0.40) | CYP4F2CYP4A11IDO1PNMTTAAR1 | |
| SCHEMBL10128 | 0.80 | IDO1 (0.58) | CYP4F2CYP4A11IDO1PNMTTAAR1 | |
| SCHEMBL29413271 | 0.80 | IDO1 (0.58) | CYP4F2CYP4A11IDO1PNMTTAAR1 | |
| SCHEMBL1363230 | 0.79 | CSNK2A1 (0.46) | IDO1PNMTTAAR1CSNK2A1 | |
| SCHEMBL11947198 | 0.79 | IDO1 (0.37) | IDO1ABL1PNMTTAAR1TSHR | |
| SCHEMBL263603 | 0.79 | NOTUM (0.44) | IDO1ABL1PNMTTAAR1TSHR | |
| SCHEMBL18644044 | 0.79 | IDO1 (0.37) | IDO1ABL1PNMTTAAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023107630-A2 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107630-A2 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20200146289-A1 | Herbicidal pyrimidine compounds | BASF SE (DE) | 2020-05-14 | — | — | US | disclosed |
| EP-3638033-A1 | HERBICIDAL PYRIMIDINE COMPOUNDS | BASF SE (DE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018229041-A1 | HERBICIDAL PYRIMIDINE COMPOUNDS | BASF SE (DE) | 2018-12-20 | — | — | WO | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| CN-104470895-B | The purposes of N [3 (2 carboxy ethyl) phenyl] piperidinyl-1 yl acetamide derivatives and its activator as soluble guanylate cyclase | 拜耳制药股份公司 | 2017-04-05 | — | — | CN | disclosed |
| WO-2008077483-A1 | PYRIMIDINYL PYRAZOLES AS INSECTICIDES AND PARASITICIDE ACTIVE AGENTS | BAYER CROPSCIENCE AG (DE) | 2008-07-03 | — | — | WO | disclosed |
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-05 | — | — | US | disclosed |
| US-7297816-B2 | Sulfonamide compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-20 | — | — | US | disclosed |
| WO-2007090748-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1797083-A1 | SULFONAMIDE COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006036670-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069286-A1 | Sulfonamide compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | CCKAR, CCKBR, GRPR | CYP4F2 2236/4885CYP4A11 3946/4885IDO1 3043/4885 |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | CYP1B1, CYP4B1, ABCG2 | CYP4F2 47/4885CYP4A11 91/4885IDO1 1831/4885 |
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | AADAT, SLC1A2, SLC1A1 | CYP4F2 1265/4885CYP4A11 1534/4885IDO1 478/4885 |
| US-20060069286-A1 | Sulfonamide compounds | CCKAR, CCKBR, TAS1R2 | CYP4F2 4146/4885CYP4A11 3169/4885IDO1 3885/4885 |
| US-20200146289-A1 | Herbicidal pyrimidine compounds | DPYD, DHFR, TYMP | CYP4F2 508/4885CYP4A11 1288/4885IDO1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.